Swiss Ingredient company Evolva announced that it will sponsor a study to be conducted by the University of Newscastle, Australia, on the effect of daily resveratrol supplementation on cognitive and bone health in postmenopausal women.
Leading the study is Rachel Wong and Peter Howe of the Clinical Nutrition Research Center. The study will add on to an earlier research project by Wong, which found that resveratrol can play a role in slowing cognitive decline in Type 2 diabetes. This study was presented at the 2015 World Diabetes Congress.
No date or timeline have been announced yet for this latest study.
“According to the World Health Organisation, the number of individuals over 60 years old with diabetes will increase from 605 million patients to 2 billion,” the company said in a press release, highlighting why they feel the study is important. “As people live longer there will be a dramatic increase in the number of older people experiencing diseases linked with ageing and cognitive decline such as dementia and Alzheimer’s.”
Evolva markets resveratrol as a nutritional supplement ingredient in the US and Europe and is currently developing additional human and animal health applications.